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ABSTRACT30
Acquisition of a mucoid phenotype by Pseudomonas sp. in the lungs of cystic fibrosis (CF) 31
patients, with subsequent over-production of extracellular polymeric substance (EPS), plays 32
an important role in mediating the persistence of multi-drug resistant (MDR) infections.  The 33
ability of a low molecular weight (Mn=3200 g mol-1) alginate oligomer (OligoG CF-5/20) to 34
modify biofilm structure of mucoid Pseudomonas aeruginosa (NH57388A) was studied in 35
vitro using scanning electron microscopy (SEM), confocal laser scanning microscopy 36
(CLSM) with Texas Red (TxRd®)-labelled OligoG and EPS histochemical staining.37
Structural changes in treated biofilms were quantified using COMSTAT image-analysis 38
software of CLSM z-stack images, and nanoparticle diffusion. Interactions between the 39
oligomers, Ca2+ and DNA were studied using molecular dynamics simulations (MDS), 40
Fourier transform infrared spectroscopy (FTIR) and isothermal titration calorimetry (ITC). 41
Imaging demonstrated that OligoG treatment (>0.5%) inhibited biofilm formation,42
demonstrating a significant reduction in both biomass and biofilm height (17.8 vs. 5.5 µm; P43
<0.05). TxRd®-labelled oligomers readily diffused into established (24 h) biofilms. OligoG 44
treatment (≥2%) induced alterations in the EPS of established biofilms; significantly reducing45
the structural quantities of EPS polysaccharides, and extracellular (e)DNA (P <0.05) with a 46
corresponding increase in nanoparticle diffusion (P<0.05) and antibiotic efficacy against 47
established biofilms. ITC demonstrated an absence of rapid complex formation between 48
DNA and OligoG and confirmed the interactions of OligoG with Ca2+ evident in FTIR and 49
MDS.  The ability of OligoG to diffuse into biofilms, potentiate antibiotic activity, disrupt 50
DNA-Ca2+-DNA bridges and biofilm EPS matrix highlights its potential for the treatment of 51
biofilm-related infections.52
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INTRODUCTION55
Biofilm-associated infections with Gram-negative opportunistic Pseudomonas sp. 56
represent a formidable challenge in a range of human diseases, from non-healing skin wounds 57
to chronic respiratory disease.  In cystic fibrosis (CF), the colonization of the lung with 58
Pseudomonas aeruginosa is associated with chronic inflammation and deterioration of lung 59
function, leading to a significant increase in morbidity and mortality.1  Longitudinal studies in 60
CF have demonstrated that initial pseudomonal colonisation occurs by wild-type (non-61
mucoid) P. aeruginosa.  With disease progression and adaptation to the lung environment, P. 62
aeruginosa may acquire a mucoid phenotype, with over-production of the exopolysaccharide 63
alginate2, arising predominantly from mutations in mucA.364
Within biofilm structures, bacteria exhibit increased resistance to conventional 65
antibiotic therapies (up to 103-fold)4,5 via a range of indirect and direct mechanisms.  These 66
factors include resistance to host-mediated innate and adaptive immune responses6, 67
sequestration of antibiotics in the bacterial periplasm7, reduced bacterial metabolic activity868
and development of associated persister cells.9  Specific genetic changes may include 69
activation of stress responses e.g. efflux-pumps, 10 and the density-dependent expression of70
quorum-sensing (QS) signalling molecules.11  These factors confer significant ‘fitness’ 71
advantages for biofilm cells when compared with their planktonic-grown isogenic 72
counterparts.73
Although imprecisely defined, bacterial extracellular polymeric substance (EPS) 74
consists mainly of polysaccharides, proteins, lipids and nucleic acids (RNA and extracellular 75
DNA; eDNA) and facilitates biofilm formation and maturation.12,13  The effects of eDNA on 76
formation and maturation are mediated, in part, via its direct interaction with calcium (Ca2+) 77
within the biofilm, which induces bacterial aggregation via “cationic bridging”.14 78
Extracellular Ca2+ also plays an important role within the biofilm in modifying bacterial cell-79
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surface charge, facilitating cellular aggregation and the adherence of bacteria to 80
material/tissue surfaces15 by positively charged Ca2+ ions overcoming the electrostatic 81
repulsion between negatively-charged biofilm components.  P. aeruginosa can exhibit 82
distinct differences in the composition of their EPS biofilm matrices; the precise composition 83
being strain- and age-dependent and also strongly influenced by environmental conditions 84
e.g. pH, oxygen tension, nutrient availability.12,16  Studies have previously attempted to 85
define and quantify the EPS component of pseudomonal biofilms17-20 and study their 86
distribution in biofilm assembly via selective staining.20-2387
Non-mucoid P. aeruginosa strains produce two important polysaccharides which are 88
involved in biofilm formation namely, Pel (a cationic exopolysaccharide composed of 1-4 89
linked galactosamine and glucosamine sugars)24 and Psl (a penta-saccharide composed of D-90
glucose, D-mannose and L-rhamnose)25.  In non-mucoid strains, Psl/Pel predominates in the 91
biofilm matrix, while alginates predominate in biofilms produced by mucoid strains.26 The 92
alginates of mucoid Pseudomonas sp. are anionic, linear polymers composed of β-D-93
mannuronic acid (M) and α-L-guluronic acid (G) with a high molecular weight (Mw; 120-94
480 kDa).27 The persistence of pseudomonal infection within the CF lung has, in part, been 95
hypothesised to relate to the emergence of the multi-drug resistant (MDR) mucoid 96
phenotype6,28, with over-production of the alginate exopolysaccharide matrix providing 97
structural integrity to bacterial microcolonies within the diseased lung.29 The currently 98
available treatments for pseudomonal infections in the CF lung (via inhaled, oral or 99
intravenous antibiotic therapies) unsurprisingly have limited efficacy in total biofilm 100
eradication.  A large unmet clinical need therefore exists for effective antibiofilm therapies in 101
human disease.30  102
A number of antibiofilm therapeutic strategies have been employed.  EPS disruption 103
strategies (including the use of alginate lyase) have, despite advances in enzyme engineering, 104
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so far proved ineffective.31  More recently, products derived from the marine environment 105
have been investigated for antimicrobial/anti-biofilm activity e.g. furanones from the red 106
algae Delisea pulchra.32,33  However, none of these potential therapeutic approaches are as 107
yet in clinical use.108
Work in our laboratory has demonstrated the ability of a low molecular weight 109
antimicrobial agent, OligoG CF-5/20, (an alginate oligosaccharide derived from the marine 110
algae Laminaria hyperborea with a G content >85%), to inhibit Gram-negative bacterial 111
growth and potentiate (synergistically enhance) conventional antibiotics against bacteria in 112
planktonic systems (by up to 512-fold) in the non-mucoid P. aeruginosa PAO1.34  Recent in 113
vitro studies have also demonstrated the ability of OligoG to potentiate the activity of colistin 114
against mucoid CF isolate P. aeruginosa NH53788A35 and induce in vivo biofilm disruption 115
in a murine lung infection model.36  We hypothesised that the observed potentiation of 116
antibiotics against mucoid P. aeruginosa NH57388A was, in part, a direct result of the 117
interaction of OligoG with the EPS component of the bacterial biofilm.  To test this 118
hypothesis in vitro, we studied the interaction of OligoG with EPS, and specifically eDNA, in 119
pseudomonal biofilms using fluorescently-labelled oligomers and nanoparticle diffusion to 120
directly quantify these interactions.  121
122
RESULTS123
OligoG inhibits in vitro mucoid biofilm formation.  Scanning electron microscopy (SEM)124
imaging demonstrated a dose-dependent reduction in P. aeruginosa NH57388A bacterial 125
density and biofilm growth in the presence of OligoG (Fig. 1A).  This biofilm inhibition was 126
quantified and confirmed with COMSTAT analysis of confocal laser scanning microscopy 127
(CLSM) z-stack images, showing that OligoG (>2%) significantly disrupted biofilm growth 128
in a dose-dependent manner, exemplified by decreased mean biofilm bio-volume and 129
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thickness and increased roughness coefficient following treatment (Fig. 1B and C; P <0.05).  130
CLSM imaging also revealed that the presence of OligoG was associated with dose-131
dependent bacterial aggregation, which was particularly evident at concentrations >0.5%.  132
OligoG disrupts established in vitro mucoid biofilms.  Growth of P. aeruginosa133
NH57388A for 24 h generated well-defined 3-dimensional biofilm structures (mean thickness 134
of 17.8 ± 5.2 µm).  CLSM imaging and COMSTAT analysis revealed that the effect of 135
OligoG on these established biofilms was time-dependent (Fig. 2).  Although treatment for 1 136
h appeared to have no effect on biofilm structure (see Fig. S1), 4 h treated biofilms showed a 137
dose-dependent reduction in biofilm thickness at OligoG concentrations ≥2%, and a 138
significant increase in roughness coefficient at OligoG concentrations ≥6% (P <0.05; Fig. 139
2A).  After 24 h treatment there was a more marked reduction in biofilm bio-volume and a 140
significantly decreased biofilm thickness with increased OligoG concentrations (P <0.05; 141
Fig. 2B).  These effects were also dose-dependent, with significantly increased roughness 142
coefficients and a decrease in the numbers of non-viable bacterial cells observed with 143
increasing OligoG concentration in the treated samples (P <0.05; Fig. 2B).   144
Texas red (TxRd®) labelling studies demonstrate diffusion of the oligomer into 145
mucoid biofilms. OligoG was labelled with Texas red (TxRd®) to facilitate visualisation of 146
OligoG within the biofilms (Fig. S2A).  CLSM images of OligoG (≥0.5%) treated P. 147
aeruginosa (NH57388A) biofilm formation (24 h) (see Fig. 3A) and biofilm disruption (see 148
Fig. S3B) showed TxRd®-associated fluorescence was distributed throughout the whole 149
biofilm structure.  Furthermore, CLSM images emphasised the biofilm inhibitory and 150
disruptive properties of TxRd®-OligoG, displayed by a significant dose-dependent decrease 151
in mean biofilm bio-volume and increase in roughness coefficient with increasing TxRd®-152
OligoG concentrations for both biofilm formation (see Fig. S4A) and biofilm disruption (see 153
Fig. S4B) assays (P <0.05).154
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Although un-conjugated “free” TxRd® dye was shown to penetrate to the base of the 155
biofilm, this was not associated with alteration of biofilm architecture or bacterial 156
aggregation (see Fig. S4C).  In contrast, penetration of the labelled OligoG to the base of 157
established biofilms was associated with bacterial aggregation (Fig. S2C).  Analysis of the 158
supernatant by size exclusion chromatography demonstrated that there was no detectable free 159
TxRd® present, thereby confirming that TxRd® was not released from OligoG during the 160
experiment (Fig. S2B; TxRd® eluted at >5.5 ml).  161
OligoG does not cause an increase in planktonic cell numbers after treatment of 162
established biofilms.  To determine the effect of the oligomers on possible dispersal of 163
planktonic cells following treatment of established (24 h) biofilms, analysis of the cell 164
supernatant was performed.  This revealed that the observed decrease in biofilm bio-volume 165
and thickness (Fig. 2B) was not directly related to increased numbers of planktonic cells in 166
the growth medium following 24 h OligoG treatment.  Instead, there was a dose-dependent 167
decrease in planktonic cells that was significant at 6% OligoG (P <0.05; see Fig. S5), 168
presumably as a direct result of reduced growth following treatment. 169
OligoG disrupts EPS within the mucoid biofilm matrix. P. aeruginosa170
NH57388A biofilms were stained to visualize different components of the biofilm using 171
SYPRO® Ruby Red (proteins; see Fig. S6), Alexa Fluor 633-labelled Concanavalin A (α-D-172
glucose and α-D-mannose) and TOTO-1 (eDNA) (Fig. 3A and B).20,21 SYPRO® Ruby Red 173
staining demonstrated a dose-dependent inhibition of biofilm matrix formation (specifically 174
the protein component of the biofilm) with increasing OligoG concentration (see Fig. S6).175
However, this same trend was not observed in fluorescence intensities quantified from CLSM 176
images achieved using Concanavalin A and TOTO-1 staining (Fig. 3A), which revealed no 177
significant changes in fluorescence intensity (for either polysaccharides or eDNA 178
respectively) during biofilm formation following OligoG treatment (Fig. 3C).  Instead, from 179
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the CLSM images of biofilm formation, there appeared to be a change in the distribution of 180
the ConA staining following OligoG treatment (>0.5%), with a trend towards smaller clusters 181
of ConA-stained EPS components (polysaccharides) (Fig. 3A).  In contrast, CLSM images 182
(Fig. 3B) and corresponding fluorescence intensity measurements of P. aeruginosa183
NH57388A 24 h established biofilms treated with OligoG, revealed a significant dose-184
dependent reduction in the fluorescence intensity of both ConA and TOTO-1 staining 185
following treatment (P <0.05), indicating biofilm disruption through reduction in both the 186
polysaccharides and eDNA components of the biofilm matrix (Fig. 3D).   187
OligoG treatment increases nanoparticle diffusion within biofilms.  A Transwell®188
biofilm diffusion assay was developed employing fluorescent nanoparticles to measure 189
particle diffusion through biofilms, treated with/without OligoG for 4 h (see Fig. 4A). OligoG 190
treatment (2%) of biofilms increased the diffusion of fluorescent nanoparticles at 1 h and 2 h 191
incubation after nanoparticle addition (Fig. 4B and C), which was significantly different at 192
the 1 h time point (P <0.05).193
 OligoG acts synergistically with the antibiotic erythromycin and tobramycin 194
against biofilms.  Minimum inhibitory concentration (MIC) assays and CLSM imaging were 195
performed to visualise the potential synergy between OligoG and the antibiotics 196
erythromycin and tobramycin.  The MIC for erythromycin was reduced four-fold against the 197
P. aeruginosa NH57388A, from 128 g ml-1 (0% OligoG) to 32 g ml-1 after treatment with 198
6% OligoG, whilst the MIC for tobramycin against P. aeruginosa NH57388A remained 199
unchanged with OligoG treatment (1 g ml-1).  CLSM images also showed increased biofilm 200
disruption and increased numbers of non-viable cells in biofilms treated with 2% OligoG and 201
128 g ml-1 (MIC value) erythromycin, in contrast to the erythromycin-only treated control 202
(see Fig. S7). In biofilms treated with 2% OligoG and 1 g ml-1 (MIC value) tobramycin 203
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whilst disruption of the treated biofilms was also evident, no similar increase in non-viable 204
cells was observed (Figure S7). 205
Molecular dynamics simulations (MDS) demonstrated contrasting interactions of 206
OligoG with calcium and DNA.  MDS modelling demonstrated the ability of Ca2+ ions to 207
rapidly bind pseudomonal DNA (in < 1ns; Fig. 5A), illustrating clearly how Ca2+-DNA-Ca2+208
“bridges” may be formed in vivo (between individual DNA molecules in ~ 60 ns; Fig. 5B).  209
Ca2+ binding appeared to initiate the formation of these bridges, and once formed, the bond 210
remained stable, while further bridging occurred.  Addition of OligoG (DPn 16) in these 211
models (Fig. 5C), demonstrated its interaction with the Ca2+ ions both present in the Ca2+-212
DNA-Ca2+ “bridges” and its rapid sequestration of free Ca2+ ions.  The simulation revealed 213
the ability of the oligosaccharide to invade the structural assembly and disrupt these existing 214
bridges between adjacent DNA molecules, resulting in the formation of stable DNA-Ca2+-215
OligoG-Ca2+-DNA bridged complexes (Fig. 5D).  The simulations, in which “free Ca2+” ions 216
were removed, revealed the limited ability of OligoG to remove Ca2+ molecules already 217
bound to DNA.218
OligoG exhibits contrasting molecular interactions with calcium and DNA.  The 219
interaction of the alginate oligosaccharide, OligoG, with Ca2+ ions was also readily 220
demonstrated by FTIR (Fig. 6A) being evident in peak-shift, most markedly in the 221
“glycogen-rich” region of the spectrum (1200-900 /cm; Fig. 6B). The lack of novel peaks 222
suggested that Ca2+ ions interact with OligoG via specific molecular interactions, via 223
electrostatic and/or ionic interactions, influencing the stretching/bending moments of the C-O 224
bonds characteristic of this region. By contrast, FTIR spectral analysis failed to demonstrate225
any major differences in the OligoG spectra following DNA treatment, with little change in 226
peak positions (see Fig 6B).227
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OligoG does not show instantaneous interactions with DNA.  The interactions of 228
OligoG with DNA in the presence of 1 mM and 5 mM Ca2+ were studied using isothermal 229
titration calorimetry (ITC).  The heat effects for dilution of OligoG in the presence of Ca2+230
were not constant, indicating self-aggregation of OligoG.  In the presence of 1 mM Ca2+, the 231
observed dilution heat effects were endothermic (Fig. 6C) whereas they were exothermic in 232
the presence of 5 mM Ca2+ (Fig. 6D).  In the presence of 5 mM Ca2+ the dilution heat effects 233
showed stronger variation than in the presence of 1 mM Ca2+, suggestive of synergy in the 234
process of calcium binding to alginates at higher Ca2+ concentrations.  Comparison of the 235
molar heat effects for dilution of OligoG into buffer with the molar heat effects for titration of 236
OligoG into DNA however, showed no significant differences.  Hence, in the presence of 1-5 237
mM Ca2+, interactions between DNA and OligoG were either too weak or occurred on too 238
long a timescale (longer than tens of seconds) to be detected using ITC.  Increasing the DNA 239
concentration to 10 mM DNA in the presence of both 1 mM and 5 mM Ca2+ demonstrated the 240
same trend in the presence of OligoG (see Fig. S8B and C).241
242
DISCUSSION243
Bacterial biofilms represent a considerable challenge for antimicrobial therapy.  Therefore, in 244
the development of novel therapeutic approaches, it is important to determine the extent to 245
which such new drugs can penetrate the biofilm and disrupt the components of the EPS.37246
The observed inhibition of pseudomonal biofilm formation in the presence of OligoG is in 247
accord with previous in vitro AFM force-measurement and rheological studies, where OligoG 248
induced discrete mechanical alterations within biofilms.38 Also, a recent in vivo murine lung 249
infection model study36 confirmed that OligoG disrupted biofilm formation in a dose-250
dependent manner. The mechanisms by which these changes may occur in developing 251
biofilms, may relate to several previously-described effects of the alginate on planktonic P. 252
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aeruginosa PAO1 including: binding to the Gram-negative bacterial cell surface, forming 253
microbial aggregates complexes with OligoG39, inhibition of growth,34 decreased bacterial 254
surface attachment,40 modulation of surface charge (zeta potential) and reduction of bacterial 255
motility.39  All of these effects could readily modify biofilm formation.  However, these 256
mechanisms would not affect the marked disruption evident in the dense (approximately 20 257
m thick), established (24 h) NH57388A biofilms.  The dose-dependent disruption of 258
established biofilms with oligomer treatment was however, clearly evident from the 259
COMSTAT analysis;41 characterised by marked decreases in biofilm bio-volume (up to 3-260
fold reduction) and mean thickness.   261
A potential mechanism by which anionic low Mw oligomers might act in established 262
biofilms is via disruption of the EPS components of the biofilm matrix.42  We hypothesised 263
that gross, dose-dependent biofilm disruption would necessitate the effective diffusion of 264
OligoG throughout the whole biofilm matrix.  The use of labelled oligomers allowed us to 265
study the ability of OligoG to diffuse into the complex, “branching” mesh of the hydrated 266
biofilm EPS.  TxRd®-labelled OligoG could be seen throughout the biofilm network, both 267
during biofilm formation (formed in the presence of treatment) at OligoG concentrations as 268
low as 0.5%, and also after treatment of established biofilms, demonstrating effective 269
diffusion of the negatively-charged oligomers into the biofilm structure and their ability to 270
induce bacterial aggregation (in contrast to the TxRd® control).  This study confirmed that the 271
efficacy of OligoG was not biofilm surface-restricted and moreover, that TxRd®-labelling did 272
not impair the anti-biofilm effects of OligoG. 273
The importance of eDNA in pseudomonal biofilm architecture has been demonstrated 274
in directing both cell-surface attachment43,44 and providing mechanical stability14.  Within the 275
diseased lung, eDNA may be derived from autolysis of the biofilm bacteria and host-derived 276
immune cells.21  No apparent difference in the quantity of eDNA was observed in biofilms 277
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formed in the presence of OligoG.  Therefore, the ability of OligoG to inhibit biofilm 278
formation may be related to the previously described activity of the oligomers on planktonic 279
Gram-negative bacteria, such as P. aeruginosa PAO1, where treatment modified bacterial 280
growth,34 cell-surface charge,39 and inhibits bacterial attachment40.  In contrast, imaging 281
studies of established biofilms demonstrated the ability of OligoG (≥2%) to significantly 282
reduce biofilm eDNA.  Interestingly, the previously demonstrated ability of the oligomers to 283
modify pilE gene expression and swarming motility in P. aeruginosa,39 and induce dose-284
dependent reductions (>0.2%) in non-mucoid pseudomonal QS signalling35,45 suggests that 285
modulation of QS signalling within the biofilm environment may also play a direct role in 286
mediating the observed changes in biofilm architecture and eDNA.287
Lectin staining combined with CLSM imaging provided not only a visual 288
demonstration of the effects of OligoG on the EPS biofilm matrix, but also enabled 289
quantification of the structural changes in the biofilm matrix.  ConA staining with CLSM 290
imaging demonstrated that the oligomers morphologically altered the distribution of EPS 291
polysaccharides during biofilm formation and also following treatment of established 292
biofilms; fluorescence intensity measurements revealed significantly decreased 293
polysaccharides in the oligomer-treated established biofilms.  The glucose-rich 294
polysaccharide Pel (a cationic EPS component produced during P. aeruginosa biofilm 295
formation) is involved in cell-to-cell interactions,17 and has recently been demonstrated to 296
ionically cross-link eDNA within the biofilm matrix,24 whilst the mannose-rich Psl (a key 297
constituent of biofilm scaffolding) mediates both cell-surface and cell-cell interactions18-20.  298
Kundukad et al.46 recently demonstrated that differences in Psl concentration (occurring with 299
biofilm maturation) resulted in altered mechanical properties of biofilms.  Moreover, it has 300
been hypothesised that pseudomonal rugose small-colony variants, expressing increased 301
levels of Pel and Psl, might play an important role in mediating bacterial persistence 302
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following prolonged antibiotic treatment, within the CF lung.47  Pseudomonal alginates are 303
also key components of the biofilm matrix in the diseased CF lung and contribute to the 304
thick, viscous mucus.48 Mucoid strains of P. aeruginosa typically produce high-Mw (>15 305
kDa) naturally acetylated alginates13 which lack consecutive G-residues and contribute to the 306
mechanical strength of the biofilm, via chelation of divalent cations (e.g. Ca2+ and Mg2+).49307
Due to the structural importance of the EPS in maintaining biofilm physiology, numerous 308
strategies have been developed in an attempt to effect EPS disruption including the use of 309
alginate lyase, DNase and hydrolase-based approaches.30,50,51  OligoG may also modify the 310
structure of EPS via its ability to bind divalent cations, e.g. Ca2+ and Mg2+, which are 311
involved in regulating EPS and eDNA interactions within the biofilm scaffold;43,48 Ca2+ also 312
appearing to play an important role in the switch in P. aeruginosa from acute to chronic 313
virulence52.  Chelation by OligoG results from the Ca2+-binding affinity of the conformational 314
arrangement of the G-block co-polymer.  Alginates, such as OligoG, are known to interact 315
with Ca2+ in a dose-dependent process, displaying auto-cooperativity53-56 and the recently 316
observed ability of OligoG to modify the assembly of the dense CF intestinal mucus has been 317
hypothesised to occur via chelation of Ca2+.57,58,59  Bacterial polysaccharides, Ca2+ and eDNA 318
are key, inter-related components of biofilms which direct assembly, architecture and 319
resistance to therapy.14,58  Disruption of these important biofilm matrix components by the 320
negatively-charged OligoG could have contributed to the observed changes in bio-volume 321
and biofilm thickness in both biofilm formation and treated established biofilms.  It is 322
important to note however, that ConA binding is not solely restricted to α-D-glucose and α-323
D-mannose; Con A may also label high-molecular weight bacterial-derived alginate block co-324
polymers, within the biofilm structure.22325
Previously, Ca2+-mediated interactions between the LPS of Gram-negative bacteria 326
and OligoG60 and DNA61 have been demonstrated.  Instead here, we studied the potential 327
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interactions between OligoG and DNA mediated by Ca2+ that could occur within 328
pseudomonal biofilms. MD simulations suggested that OligoG might effectively disrupt the 329
assembly of new DNA-Ca2+-DNA bridges in biofilm development, in keeping with the 330
CLSM studies.  The ability of OligoG to “invade” these established DNA-Ca2+-DNA 331
networks was supported by the effective diffusion of fluorescently-labelled oligomers into 24 332
h biofilms.  This proposed invasion/disruption may be reflected in the previously altered 333
viscoelastic properties of OligoG-treated pseudomonal biofilms.38  Furthermore, the MD 334
simulations suggested that, once bound, the “free end” of the oligomer retained the ability to 335
bind free-Ca2+ (and adjacent OligoG molecules).  This finding may explain the dose-336
dependent aggregation in the treated samples observed here, and in previous studies.39 The 337
ITC experiments (at higher Ca2+ concentrations) also reflected this Ca2+-dependent, self-338
aggregation of OligoG.   339
The MD simulations suggested the importance of the interactions with Ca2+, rather 340
than direct interactions of the OligoG with the DNA in our biofilm models.  It must be noted 341
however, that the simulation was designed to study Ca2+-DNA interactions, (and other 342
divalent cations e.g. Mg2+ which are also bound by the oligosaccharides) which may be 343
modified in vivo.  FTIR showed a lack of apparent molecular interaction between OligoG and 344
DNA.  Furthermore, ITC demonstrated that, even in the presence of calcium, OligoG and 345
DNA do not interact instantaneously, suggesting that the biofilm-disrupting effects of OligoG 346
are not the result of a (rapid) Ca2+-- mediated interaction between OligoG and eDNA and 347
would not induce immediate biofilm destabilisation.  The lack of instantaneous interactions 348
between OligoG and DNA is in agreement with the observed time-dependent disruption of 349
treated established biofilms.  Whilst all of these in vitro experiments do not reproduce the 350
complex relationship that exists between eDNA, Ca2+ and bacterial polysaccharides within 351
biofilms in vivo, they are useful models to study potential interactions.  352
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Elevated levels of cations (up to 120 mg l-1 Ca2+) are evident locally in the diseased 353
lungs of CF patients and have been hypothesised to contribute to the severity of disease.62354
Several studies have consequently considered the possible therapeutic utility of chelating 355
agents to enhance biofilm disruption and facilitate antibiotic potentiation in vitro.63  In 356
contrast to ‘broad-spectrum’ chelating agents such as EDTA, OligoG lacks toxicity issues.  357
Hence in terms of CF treatment, the effect of OligoG on both divalent cations and eDNA is 358
highly beneficial for these patients, in whom pulmonary levels of Ca2+ and Mg2+ may be 359
elevated. 360
OligoG has been proven to be safe for inhalation therapy and has been shown to alter 361
the viscoelasticity of CF sputum.64  OligoG has been demonstrated to not only reduce 362
bacterial load within biofilm structures, but also to target and disrupt the EPS matrix of 363
established biofilm architecture.  Conceptually, this disruption of established biofilms may 364
facilitate penetration of the biofilm-coated lung surface, which is an effective barrier to the 365
delivery of pharmaco- and gene-therapy across the lung-surface in disease.37  To test this, we 366
utilised a fluorescent, particle-diffusion model using biofilms in a Transwell® system, which 367
has recently been used to study fluorescent particle permeation through mucus.65  Negatively-368
charged particles were employed since the EPS matrix of biofilms also has an overall 369
negative net charge66 and a number of negatively-charged antibiotics may also be used in the 370
treatment of Gram-negative biofilm infections e.g. ciprofloxacin25, 67.  The transwell® assay, 371
developed here to model diffusion through bacterial biofilms, has the advantage of measuring 372
the ‘bulk’ properties of the entire biofilm.  In this model, it was clear that the dose-dependent 373
increase in biofilm disruption and decreased thickness evident from the CLSM imaging was 374
also reflected in increased particle diffusion.  Although significantly increased diffusion was 375
observed in the transwell® assay, the standard deviations were relatively high, indicating 376
possible pore-blockage68 and/or the non-uniformity of biofilm disruption observed in the 377
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CLSM imaging.  These experiments used oligomer concentrations of ≤2% to facilitate rinsing 378
of the biofilms.  Despite these issues, the results revealed the utility of the transwell® particle 379
diffusion assay to model the efficacy of anti-biofilm strategies.  380
Baker et al.69 recently demonstrated that the biofilm EPS-disrupting ability of glycoside 381
hydrolases (PelAh and PslGh) was accompanied by potentiation of the antibiotic colistin.  382
Workers have recently demonstrated ability of OligoG to synergistically enhance the activity 383
of colistin against P. aeruginosa NH57388A in minimum biofilm eradication concentration 384
assays.36 We showed here that OligoG also potentiated the antibiofilm activity of the 385
macrolide antibiotics, erythromycin and tobramycin against P. aeruginosa NH57388A 386
biofilms. The results were contrasting, and not as marked in tobramycin, which may reflect, 387
in part, the interaction of the anionic OligoG, with the polycationic tobramycin. Interestingly, 388
in addition to disruption of the EPS, the ability to potentiate antibiotic activity against 389
biofilms described here may also be mediated via the ability of OligoG to modify 390
pseudomonal motility,34 where Chua et al.70 recently demonstrated the importance of motility 391
in the acquisition of colistin resistance within pseudomonal biofilm communities. 392
These studies demonstrate the effects of the inhaled alginate oligomer therapy, OligoG, 393
in impairing the formation and facilitating disruption of mucoid biofilms.  Whilst the 394
mechanisms of disruption of biofilm EPS matrix and the modification of eDNA assembly in 395
the biofilms may be regulated indirectly (via QS signalling) these studies demonstrate the 396
mechanistic importance of direct interaction of OligoG with Ca2+ and the resultant 397
modification of intercellular bridges within the Ca2+- DNA biofilm mesh. 398
The direct and indirect anti-biofilm effects, coupled with the safety and tolerability of 399
OligoG CF-5/20 may have potential clinical utility in the management of biofilm-related 400
Gram-negative infections.  Phase IIb clinical studies are ongoing in CF patients 401
(www.ClinicalTrials.gov [NCT02157922], [NCT02453789]).402
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403
MATERIALS AND METHODS404
Alginate Oligosaccharide Synthesis (OligoG).  OligoG CF-5/20 was produced from 405
the stem of the brown seaweed Laminaria hyperborea and purified and fractionated as 406
previously described.32 This resulted in a low molecular weight (mean Mn 3,200 g mol-1) 407
alginate oligomer possessing a high guluronate content (>85%) with a degree of 408
polymerization [DPn] of 16.409
Bacterial strains and media.  A mucoid, CF P. aeruginosa clinical isolate 410
(NH57388A) was used in this study.71,72,73  Bacterial colonies were grown on blood agar no.2 411
(BA; Lab M) supplemented with 5% horse blood.  Overnight cultures were grown in tryptone 412
soya broth (TSB; Lab M) at 37oC, with shaking. Cultures were adjusted to 107 cfu ml-1413
(~OD600 0.05)74 before use in the following experiments.   414
Effect of OligoG as a treatment to inhibit biofilm formation (SEM).  Mueller 415
Hinton (MH) broth (Lab M) ± 0.5%, 2% or 6% OligoG (w/v) was prepared in a 12-well plate 416
(Greiner Bio-One, Stonehouse, UK) containing ThermanoxTM slides (Agar Scientific), 417
followed by an inoculum using a 1:100 dilution of the P. aeruginosa (NH57388A) overnight 418
culture, and incubated at 37oC with gentle rocking for 24 h.  The supernatant was then 419
removed and biofilms fixed with 2.5% (v/v) glutaraldehyde for 1.5 h.  Following washing 420
(x4) with dH2O, the fixed biofilms were covered with 1 ml dH2O, frozen and then freeze-421
dried.  Imaging was performed using Hitachi S4800 SEM without sputter coating.422
Effect of OligoG as a treatment to inhibit biofilm formation (CLSM).  For CLSM 423
imaging, P. aeruginosa NH57388A biofilms were grown in Whatman 96-well glass-bottomed 424
plates in MH broth ± 0.5%, 2% or 6% OligoG (or TxRd®-labelled OligoG).  A 1:10 inoculum 425
of the P. aeruginosa (NH57388A) overnight culture was used and plates were incubated at 426
37oC for 24 h. 427
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Effect of OligoG as a treatment to disrupt established biofilms and to potentiate 428
the effect of erythromycin and tobramycin. P. aeruginosa NH57388A biofilms were 429
grown in Whatman 96-well glass-bottomed plates in MH broth using a 1:10 (v/v) inoculum 430
of overnight culture and plates were incubated at 37oC for 24 h prior to treatment.  Half the 431
supernatant was then carefully removed and replaced with fresh MH broth ± OligoG (or 432
TxRd®-labelled OligoG).  The final concentrations of OligoG used were 0.5%, 2% and 6% 433
(v/v).  The samples were then incubated at 37oC at each time point (1, 4 and 24 h) before 434
imaging.  For the erythromycin and tobramycin potentiation experiments, half the supernatant 435
was removed after 24 h biofilm growth and replaced with MH broth ± 2% OligoG and 128 436
µg ml-1 (MIC value) erythromycin (final concentration; v/v) or 1 µg ml-1 (MIC value) 437
tobramycin (final concentration; v/v) before a further 24 h incubation at 37oC. 438
Texas Red (TxRd®)-labelling of OligoG and conjugate characterisation.  To 439
follow the fate of OligoG during biofilm inhibition and disruption via CLSM, conjugation to 440
a fluorescent dye was utilised.  OligoG was labelled with TxRd® cadaverine (molecular 441
weight 690.87 g mol-1) using 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride 442
(EDC) and N-hydroxysulfosuccinimide (sulfo-NHS) as zero-length crosslinking agents (Fig 443
S2A; see supplementary information for full methodology and control experiments 444
conducted). 445
Selective staining and CLSM imaging.  Biofilm supernatants were carefully 446
removed before staining.  For the OligoG biofilm assays, the biofilms were stained with 447
LIVE/DEAD® (BacLightTM Bacterial Viability Kit, Molecular ProbesTM) for 10 min, prior to 448
imaging for bacterial visualisation.  For the TxRd®-OligoG biofilm assays, the biofilms were 449
stained with SYTO® 9 for 10 min prior to CLSM imaging.  For visualisation of protein 450
content, biofilms were stained with FilmTracerTM SYPRO® Ruby Biofilm Matrix stain 451
(Molecular ProbesTM; 4 h incubation) or stained with TOTO-1 (Molecular ProbesTM; 20 min 452
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incubation) in combination with Concanavalin A (ConA) Alexa Fluor 633 (Molecular 453
ProbesTM; 40 min incubation) for eDNA and EPS visualisation respectively.  CLSM imaging 454
of the biofilm formation and biofilm disruption assays was performed using an Olympus 455
FV1000 CLSM.  CLSM imaging of the biofilm components (SYPRO® Ruby Biofilm Matrix 456
stain, TOTO-1, Concanavalin A) and erythromycin potentiation assays was achieved using a 457
Leica SP5 CLSM.  The CLSM images were achieved with an x63 lens (oil), a step size of 458
0.7µm, line averaging of 2 and with simultaneous scanning (See supplementary information 459
for the excitation and emissions ranges of the stains used in this study). CLSM images were 460
processed using Imaris software (Bitplane, Concord, MA, USA) as maximum intensity 461
images.  The fluorescence intensities from the CLSM biofilm images achieved with ConA 462
and TOTO-1 were compiled from the Imaris program. 463
COMSTAT image analysis.  CLSM z-stack images were analysed using COMSTAT 464
image analysis software for quantification of three-dimensional biofilm structures through 465
measurement of biofilm volume, surface roughness and biofilm depth.41466
Semi-quantification of planktonic bacteria.  The supernatant removed from the 467
biofilms was placed into a 96-well plate and centrifuged at 3000 g for 10 min.  The 468
supernatant was then removed and the cell pellets re-suspended in 100 l of PBS, after which 469
1 l of crystal violet (0.5% w/v in PBS) was added into each well and the OD595 measured to 470
quantify the total biomass (live and dead) of planktonic cells. 471
Transwell® biofilm diffusion studies.  Overnight cultures of P. aeruginosa472
NH57388A were adjusted to 107 cfu ml-1, and 0.1 ml of culture together with 0.2 ml of MH 473
broth were added to the 6.5 mm transwell® (3.0 µm pore size; Corning) upper donor well, 474
while 1 ml of MH broth was added into the lower acceptor well.  The transwell® plate was 475
then placed on a rocker at 20 rpm at 37oC for 24 h.  After growth, the supernatant was 476
removed from the donor well and 100 µl of MH (± 0.5, 2, 6% OligoG) was added and 477
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incubated for a further 4 h.  The supernatant was again removed and the biofilms rinsed twice 478
in deionised water, before moving the donor transwells® to a new acceptor well containing 479
600 µl of deionised water.  Then 140 µl of 0.007% negatively-charged FluoSpheres 480
(Carboxylate-modified Microspheres, 0.2 µm; Molecular ProbesTM) in distilled water were 481
placed into each donor well and after 1 h incubation, 100 µl of distilled water was removed 482
from the acceptor well and placed into a Grenier glass-bottom 96-well black plate for 483
fluorescence reading.  A Fluostar Omega Microplate Reader was used to measure end-point 484
fluorescence (excitation 488 nm/emission 520 nm).  Readings were also taken at the 2 h 485
incubation interval. 486
Molecular dynamics (MD) simulations of calcium, DNA and OligoG CF-5/20 487
interactions.  MD simulations were all run on the High Performance Wales Supercomputer 488
(www.hpcwales.co.uk; Supporting Information).  Sequences were generated using BIOVIA 489
Discovery Studio® 2017 software (BVS).  Alginate oligosaccharides were derived from the 490
crystal structure of the molecule (PDB ID 1J1N4) and converted into 16 repeat units using 491
BVS and elongated to 16 residues; correspond to the DPn of the OligoG CF-5/20 used in the 492
in vitro experiments.  Two, 15 bp DNA sequences were generated to represent a double 493
strand, selected from the genomes of P. aeruginosa75; pseudomonal DNA sequences were 494
selected to ensure their G:C ratios were representative of P. aeruginosa as a whole (66.6%).  495
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FTIR analysis of interactions of OligoG with DNA and Ca2+.  FTIR analysis was 496
performed on samples containing OligoG, Ca2+ ion solution (1000 ppm; Cole Parmer WZ-497
27502-59) and DNA (170µg/ml; >90% at 50kB: Promega G3041) .  All samples were 498
vortexed, centrifuged at 1000 g for 30 s, before being incubated at 37°C for 30 min on a 499
plate-shaker. Five µl of each sample was then pipetted onto 96-well silicon plates (Bruker 500
Optics Inc., Billerica, MA). Following drying at room temperature for 1 h, high-throughput 501
FTIR analysis was performed using a Bruker Vertex 70 with HTS-XT attachment and a 502
DTGS detector (Bruker).  Three replicates of each sample were analysed where infrared 503
spectra were obtained and processed using the in-built tools and algorithms in OPUS 7.5. 504
Spectra were vector-normalised, baseline-corrected using the automatic “rubberband” 505
correction. 506
Isothermal Titration Calorimetry.  Buffer solutions were prepared by dissolving 507
5.84 g of NaCl, 4.19 g of MOPS, and 0.11 or 0.55 g of CaCl2 in deionised water, adjusting 508
the pH to 7.0 (Hanna Instruments pH210 microprocessor pH meter with a VWR simple 509
junction gel universal combined pH/reference electrode) using an aqueous solution of sodium 510
hydroxide, and making up the solution to 1 l.  OligoG solutions were prepared by dissolving 511
20 mg of OligoG in 1 ml of the required buffer to obtain a solution of 101 mM OligoG 512
(concentration in terms of monomeric units); OligoG solutions being used for a maximum of 513
four weeks.  DNA stock solutions were prepared by dissolving ~ 0.1 g fish sperm DNA in 10 514
ml buffer.  These solutions were dialysed (MWCO 3.5 kDa) overnight against half a litre of 515
buffer and the DNA concentration was determined spectrophotometrically (JASCO V630 516
spectrophotometer) using an extinction coefficient of 12800 M-1 cm-1 at 260 nm.76  The stock 517
solution was diluted as required to prepare 1 mM and 10 mM solutions of DNA.  For all 518
experiments, other buffer components used were 100 mM NaCl and 20 mM MOPS pH 7.0.  519
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Calorimetric titrations were carried out at 37°C on a MicroCal PEAQ-ITC 520
microcalorimeter (Malvern Instruments Ltd).  The instrument was operated by applying a 521
reference power of 10 µcal/s, in high feedback mode, stirring the sample cell contents at 750 522
rpm, with a pre-injection initial delay of 60 s.  All experiments involved an initial injection of 523
0.4 µL in 0.8 s followed by 12 further injections of 3.0 µL in 6.0 s into the calorimeter 524
sample cell.  Injections were spaced by at least 150 s to allow full recovery of the baseline.  525
Raw data was treated using MicroCal PEAQ-ITC Analysis Software (1.0.0.1259) to generate 526
integrated heat effects per injection (ΔQ). Molar heat effects per injection (ΔH) were 527
calculated using Excel (Microsoft).   528
Statistical analysis.  Statistical software (Minitab v.14; Minitab, State College, PA) 529
was used for all statistical analyses presented.  Parametric data was analysed using T-test, 530
while non-parametric data was analysed using Mann-Whitney test to determine significant 531
differences for pair-wise comparisons.  A P value of <0.05 was considered statistically 532
significant. 533
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FIGURE LEGENDS 791
792
FIG 1   Effect of OligoG on inhibition of mucoid biofilm formation: Imaging and 793
quantification of P. aeruginosa (NH57388A) biofilms grown for 24 h at 37oC in MH broth ± 794
OligoG (0.5%, 2% & 6%). (A) SEM imaging of biofilms (Scale bar, 10 µm). (B) CLSM 3D 795
imaging (aerial view) of LIVE/DEAD® staining of biofilms (Scale bar, 20 µm). (C) 796
COMSTAT image analysis of the corresponding biofilm CLSM z-stack images. *P <0.05 797
significance was determined by comparison to the untreated control. Error bars are means of 798
standard deviations (n=3).799
800
FIG 2  Effect of OligoG on disruption of mucoid established biofilms: CLSM 3D imaging 801
(side view) with LIVE/DEAD® staining of P. aeruginosa (NH57388A) biofilms grown for 24 802
h at 37oC in MH broth followed by 4 or 24 h OligoG treatment (0.5%, 2% and 6%) (Scale 803
bar, 15 µm) with COMSTAT image analysis of the corresponding biofilm CLSM z-stack 804
images. Treatment times (A) 4 h. (B) 24 h. *P <0.05 significance was determined by 805
comparison to the untreated control. Error bars are means of standard deviations (n=3). 806
807
FIG 3  3D CLSM imaging of P. aeruginosa (NH57388A) biofilms stained with concanavalin 808
A (EPS polysaccharides, red) and TOTO-1 (eDNA, green; scale bar, 8 µm) in (A) biofilm 809
formation assay, where biofilms are grown for 24 h in MH broth ± OligoG, 0.5%, 2% and 6% 810
and (B) the biofilm disruption model where biofilms grown for 24 h in MH broth, followed 811
by 24 h treatment of OligoG, 0.5%, 2% and 6%. Corresponding mean fluorescence intensities 812
(arbitrary units x106) achieved from CLSM 3D imaging of the (C) biofilm formation assay 813
and the (D) biofilm disruption assay. *P <0.05 significance was determined by comparison to 814
the untreated control. Error bars are means of standard deviations (n=3). 815
34 
816
FIG 4 (A) Schematic diagram of transwell device showing particle diffusion through the 817
biofilm and microporous membrane. Boxplots of mean fluorescence intensity (arbitrary units) 818
in the biofilm transwell assay after 4 h OligoG treatment (n=5), where fluorescence was 819
measured at (B) 1 h and (C) 2 h after fluosphere addition. *P <0.05 significance was 820
determined by comparison to the untreated control. Error bars are means of standard 821
deviations (n=3). 822
823
824
FIG 5  Molecular dynamics simulations at early and late binding of DNA double strand (15 825
bp) in the presence of Ca2+ (green spheres) at (A) 1 ns and (B) 58 ns.  G-oligomer (DPn 16) 826
was added to the simulations where the binding affinity was assessed at (C) 0 ns and (D) 50 827
ns. 828
829
FIG 6  FTIR absorbance spectra of the molecular interaction of OligoG with calcium and 830
DNA (A) from 1800-900 /cm of pure OligoG (blue), OligoG + 5mM Ca2+ (green), OligoG + 831
10 mM DNA + 5 mM Ca2+ (grey), and OligoG + 10 mM DNA (red) and (B) from 1200-900 832
/cm (colours as in A). Isothermic calorimetric titrations of 101 mM OligoG into 1 mM FS 833
DNA containing (C) 1 mM CaCl2 or (D) 5 mM CaCl2 (and corresponding reference 834
experiments); buffer into buffer (grey), buffer into DNA (red), OligoG into buffer (blue), 835
OligoG into FS DNA (green). Concentrations of OligoG and FS DNA are in terms of 836
monomeric units and base pairs, respectively. Error bars are means of standard deviations 837
(n=3).838
839
FIG S1  Effect of OligoG on disruption of mucoid established biofilms: CLSM 3D imaging 840
(aerial + side view) with LIVE/DEAD® staining of P. aeruginosa (NH57388A) biofilms 841
35 
grown for 24 h at 37oC in MH broth followed by 1 h OligoG treatment (0.5%, 2% and 6%; 842
Scale bar, 20 µm) (n=3). 843
844
FIG S2  (A) Diagrammatic summary showing TxRd® cadaverine labelling of OligoG using 845
1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) and N-846
hydroxysulfosuccinimide (sulfo-NHS) as zero-length crosslinking agents. (B) Quantification 847
of TxRd®-OligoG and unbound TxRd® using PD-10 column analysis of supernatant from 848
biofilms grown for 24 h in MH broth, followed by 24 h treatment with TxRd®-OligoG (0.5%, 849
2% or 6%). (C) CLSM 2D imaging (a single optical section taken close to the bottom of the 850
biofilm; scale bar, 10 µm) of P. aeruginosa (NH57388A) biofilms grown for 24 h in MH 851
broth, followed by 24 h treatment with 6% TxRd®-OligoG or TxRd® only (*equivalent to 6% 852
TxRd®-OligoG conjugate), with the respective MH only control.853
854
FIG S3  CLSM 3D imaging (aerial and side views) with SYTO-9® staining of P. aeruginosa855
(NH57388A) on (A) biofilm formation (biofilms grown for 24 h in MH broth ± TxRd®-856
OligoG, 0.5%, 2% and 6%; Scale bar, 10 µm) and (B) biofilm disruption (biofilms grown for 857
24 h in MH broth, followed by 24 h treatment of TxRd®-OligoG, 0.5%, 2% and 6%; scale 858
bar, 10 µm). 859
860
FIG S4 Quantification of the effect of TxRd®-OligoG on the inhibition and disruption of 861
mucoid P. aeruginosa (NH57388A) biofilms, with SYTO-9® staining (shown in Fig S3), 862
using COMSTAT image analysis of the corresponding biofilm CLSM 3D z-stack images of 863
(A) biofilm formation (biofilms grown for 24 h in MH broth ± TxRd®-OligoG, 0.5%, 2% and 864
6%; scale bar, 10 µm) and (B) biofilm disruption (biofilms grown for 24 h in MH broth, 865
followed by 24 h treatment of TxRd®-OligoG, 0.5%, 2% and 6%; scale bar, 10 µm). 3D 866
36 
CLSM imaging showing aerial (scale bar, 20 µm) and side views (scale bar, 15 µm) of P. 867
aeruginosa (NH57388A) grown for 24 h in MH broth, followed by 24 h treatment of only 868
MH broth control or TxRd® control 0.052 µg/ml [*equivalent to 6% TxRd®-OligoG 869
conjugate] imaged with SYTO® 9 staining. *P <0.05 was determined by comparison to the 870
untreated control. Error bars are means of standard deviations (n=3). 871
872
FIG S5  Quantitative analysis of planktonic bacterial cells using crystal violet staining of P. 873
aeruginosa (NH 57388A) biofilm supernatants from established biofilms (biofilm disruption 874
assay) grown at 37oC in MH broth for 24h, followed by 24 h treatment of ±  OligoG (0.5%, 875
2% and 6%) *P <0.05 significance was determined by comparison to the untreated control. 876
Error bars are means of standard deviations (n=3). 877
878
FIG S6 (A) CLSM 3D imaging of P. aeruginosa (NH57388A) biofilms grown for 24 h in 879
MH broth ± OligoG (0.5%, 2% and 6%), using SYPRO Ruby Biofilm matrix® staining (for 880
protein visualisation, red; scale bar, 30 µm). (B) Corresponding mean fluorescence intensities 881
(arbitrary units x106) achieved from CLSM 3D imaging of the biofilm formation assay.  *P882
<0.05 significance was determined by comparison to the untreated control. Error bars are 883
means of standard deviations (n=3). 884
885
FIG S7 CLSM 3D imaging (aerial view) with LIVE/DEAD® staining of P. aeruginosa 886
(NH57388A) biofilms grown for 24 h at 37oC in MH broth followed by 24 h treatment with 887
OligoG (2%) and/or erythromycin (128 g ml-1 =MIC) and Tobramycin (1 g ml-1 =MIC; 888
scale bar,  30 µm).889
890
FIG S8  (A) FTIR Inverted (peaks are pointing upwards) second derivative spectra of 1200-891
900 cm-1 with pure OligoG (green) and OligoG + 5mM Ca2+ (red). Isothermic calorimetric 892
37 
titrations of 101 mM OligoG into 10 mM FS DNA containing (B) 1 mM CaCl2 or (C) 5 mM 893
CaCl2 (and corresponding reference experiments); buffer into buffer (grey), buffer into DNA 894
(red), OligoG into buffer (blue), OligoG into FS DNA (green). Concentrations of OligoG and 895
FS DNA are in terms of monomeric units and base pairs, respectively. Error bars are means 896
of standard deviations (n=3).  897
898
899
900
901
902
903
904
0.00
0.03
0.06
0.09
0.12
0.15
0.18
D
EA
D
/L
IV
E 
ce
ll 
ra
tio
Control 0.5% OligoG 2% OligoG 6% OligoG
A
B
C
0.0
0.5
1.0
1.5
2.0
2.5
Bi
o-
vo
lu
m
e 
(µ
m
3 /µ
m
2 )
0
5
10
15
20
25
M
ea
n 
Th
ic
kn
es
s 
(µ
m
)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
R
ou
gh
ne
ss
 c
oe
ffi
ci
en
t Control
0.5% OligoG
2% OligoG
6% OligoG
** *
*
*
*
*
*
Fig 1
A0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
R
ou
gh
ne
ss
 C
oe
ffi
ci
en
t
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
0.16
0.18
D
EA
D
/L
IV
E 
ce
ll 
ra
tio
 
0.0
0.5
1.0
1.5
2.0
2.5
Bi
o-
Vo
lu
m
e 
(µ
m
3 /µ
m
2 )
0
5
10
15
20
25
M
ea
n 
Th
ic
kn
es
s 
(µ
m
)
0.0
0.5
1.0
1.5
2.0
2.5
Bi
o-
Vo
lu
m
e 
(µ
m
3 /µ
m
2 )
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
R
ou
gh
ne
ss
 C
oe
ffi
ci
en
t
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
0.16
0.18
D
EA
D
/L
IV
E 
ce
ll 
ra
tio
Control 0.5% OligoG 2% OligoG 6% OligoG
4 
h 
B
io
fil
m
s
24
 h
 B
io
fil
m
s 
B
0
5
10
15
20
25
M
ea
n 
Th
ic
kn
es
s 
(µ
m
)
Control
0.5% OligoG
2% OligoG
6% OligoG
Control
0.5% OligoG
2% OligoG
6% OligoG
* *
*
*
*
* **
Fig 2
AB
C
B
io
fil
m
 D
is
ru
pt
io
n
Control 0.5% OligoG 2% OligoG 6% OligoG 
B
io
fil
m
 F
or
m
at
io
n 
6% OligoG2% OligoG0.5% OligoGControl
140
120
100
80
60
40
20
0
Fl
o
u
re
sc
en
ce
In
te
n
si
ty
(a
rb
it
ra
ry
u
n
it
s)
6% OligoG2% OligoG0.5% OligoGControl
8
7
6
5
4
3
2
1
0
Fl
o
u
re
sc
en
ce
In
te
n
si
ty
(a
rb
it
ra
ry
u
n
it
s)
6% OligoG2% OligoG0.5% OligoGControl
25
20
15
10
5
0
Fl
o
u
re
sc
en
ce
In
te
n
si
ty
(a
rb
it
ra
ry
u
n
it
s)
* *
Biofilm Formation Biofilm Disruption
6% OligoG2% OligoG0.5% OligoGControl
1.8
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
Fl
o
u
re
sc
en
ce
u
n
it
s
(a
rb
it
ra
ry
u
n
it
s)
Concanavalin A                                   TOTO-1
Control 0.5% 
OligoG
2% 
OligoG
6% 
OligoG
Fl
uo
re
sc
en
ce
 In
te
ns
ity
 (a
rb
itr
ar
y 
un
its
)
Fig 3
Fl
uo
re
sc
en
ce
 In
te
ns
ity
 (a
rb
itr
ar
y 
un
its
)
Control 0.5% 
OligoG
2% 
OligoG
6% 
OligoG
Fl
uo
re
sc
en
ce
 In
te
ns
ity
 (a
rb
itr
ar
y 
un
its
)
Control 0.5% 
OligoG
2% 
OligoG
6% 
OligoG
Concanavalin A                                  TOTO-1
Fl
uo
re
sc
en
ce
 In
te
ns
ity
 (a
rb
itr
ar
y 
un
its
)
Control 0.5% 
OligoG
2% 
OligoG
6% 
OligoG
*
*
D
B                                                                             
2% OligoG0.5% OligoGControl
280000
260000
240000
220000
200000
180000
160000
140000
120000
Fl
ou
re
sc
en
ce
In
te
ns
ity
(a
rb
itr
ar
y
un
its
)
2% OligoG0.5% OligoGControl
280000
260000
240000
220000
200000
180000
160000
140000
120000
Fl
ou
re
sc
en
ce
In
te
ns
ity
(a
rb
itr
ar
y
un
its
)
*
Fl
uo
re
sc
en
ce
 In
te
ns
ity
 
(a
rb
itr
ar
y 
un
its
)
Control
CB
0.5% OligoG 2% OligoG
Fl
uo
re
sc
en
ce
 In
te
ns
ity
 
(a
rb
itr
ar
y 
un
its
)
Control 0.5% OligoG 2% OligoG
Fig 4
A
D
N
A 
an
d 
C
a2
+
w
ith
 O
lig
oG
D
N
A 
an
d 
C
a2
+
on
ly 1 ns
0 ns
58 ns
50 ns
C                                                                                               D
A                                                                                               B
Fig 5
A                                                                                             C
B                                                                                             D
Wavenumber/cm
Ab
so
rb
an
ce
 U
ni
ts
90095010001050110011501200
0.000
0.005
0.010
0.015
0.020
0.025
0.030
0.0350.035
0.03
0.025
0.02
0.015
0.01
0.0 5
0.000
Ab
so
rb
an
ce
 U
ni
ts
Wavenumber/cm
10001200140016001800
0.00
0.01
0.02
0.03
0.04
0.050.05
0. 4
0. 3
0. 2
0. 1
0. 0
1800 1600 1400 1200 1000
1200               1150                 1100                  1050                 1000                   950                900
Fig 6
SUPPLEMENTAL MATERIAL 
MATERIALS AND METHODS
Selective staining and CLSM imaging (cont.).   
Table 1: Excitation/emission ranges of the stains used in this study.
Texas Red (TxRd®)-labelling of OligoG and conjugate characterisation (cont.).  
Briefly, OligoG (100 mg) was dissolved in 1 ml PBS buffer (pH 7.4) in a 10 ml round-bottomed 
flask.  To this, EDC (6.7 mg, 10 molar eq.) and sulfo-NHS (6 mg, 10 molar eq.) were added, 
and the mixture left stirring for 15 mins.  Subsequently, TxRd® cadaverine (dissolved in 
dimethyl sulfoxide, DMSO; 5 mg ml-1 and stored at -20oC until use) was added (0.106 ml, 2 
molar eq.).  Then, NaOH (0.5 M) was added drop-wise to raise the pH to 8.0 and the reaction 
mixture was left stirring in the dark (5 h).  The conjugate was purified by size exclusion 
chromatography (SEC) using a disposable PD-10 desalting column containing Sephadex G25 
equilibrated with dH2O (25 ml added in total).  The entire reaction mixture was added to the 
column and 5.5 ml of the eluted dH2O was collected, lyophilised and stored at -20oC.  The 
reaction mixture was characterised by SEC prior to, and after purification, by analysis of SEC 
fractions for fluorescence (5 mg ml-1 solution in PBS).  To estimate the proportion of free and 
OligoG-conjugated TxRd® was present in the conjugate, a sample of the crude reaction mixture 
and final product were diluted to 0.5 ml with PBS.  This was added to a PD-10 column and 
Stains Excitation 
(nm)
Emission 
(nm)
LIVE/DEAD Baclight Bacterial Viability Kit – Syto 9 
(Molecular ProbesTM)
480 500
LIVE/DEAD Baclight Bacterial Viability Kit – Propidium Iodide 
(Molecular ProbesTM)
490 635
Syto 9(Molecular ProbesTM) 485 498
Film Tracer SYPRO Ruby Biofilm Matrix  (Molecular ProbesTM) 450 610
TOTO-1 (Molecular ProbesTM) 514 533
Concanavalin (ConA) Alexa Fluor 633 (Molecular ProbesTM) 632 647
Texas Red used for OligoG conjugation (Molecular ProbesTM) 590 615
fractions (0.5 ml) were collected in 0.5 ml Eppendorf tubes.  A sample of each fraction (100 
μl) was placed in duplicate into a black 96-well microtitre plate and fluorescence measured 
using a fluorescent plate reader (λex = 591 nm, λem = 612 nm, gain 1000).  The values were then 
plotted against fraction volume and bound TxRd® was expressed as percentage of total 
fluorescence measure for all fractions.  UV spectroscopy was used to determine the total 
TxRd® content of the TxRd®-OligoG conjugate.  TxRd®-loading was determined by analysing 
a 5 mg ml-1 solution in PBS and relating this to a TxRd® calibration curve (1-10 µg ml-1).  
Specific activity (μg TxRd® / mg TxRd®-labelled conjugate) was calculated using the 
following equation: 
             Specific activity              =    (μg TxRd® from UV) x % TxRd®  bound  
(μg TxRd/ mg TxRd conjugate)          100 x mg TxRd® -labelled conjugate  
Control experiments for TxRd®-labelled OligoG.  Since liberation of free TxRd® in 
the culture medium could potentially cause artefacts in the observed cell fluorescence (due to 
more rapid uptake compared to macromolecular conjugates), the levels of free TxRd® in the 
cell culture medium was analysed via PD-10 chromatography in specific experiments at the 
end of the incubation period. A sample of the culture media was added to the PD-10 column 
(0.5 ml) as described previously.  Control experiments included addition of the equivalent 
concentrations of “free” TxRd® cadaverine (0.052 μg ml-1, equivalent to 6% TxRd®-OligoG 
conjugate) to the biofilm CLSM assays.
Ability of OligoG to potentiate the effect of erythromycin in Minimum Inhibitory 
Concentration (MIC) assay. P. aeruginosa NH57388A was grown overnight in TSB and 
adjusted to 108 cfu ml-1 (~OD600 – 0.08; equivalent to 0.5 McFarland standard).  Two-fold 
antibiotic serial dilutions were prepared in MH broth ± 0.5, 2, or 6% OligoG in flat-bottom 96-
well microtiter plates (100µl in each well). The bacterial cultures were diluted 10-fold in MH 
broth, and 5 µl was added to the antibiotic serial dilutions to give a final concentration of 5x105
CFU/ml. Plates were incubated at 37°C for 18 h and MICs determined as the lowest 
concentration at which there was no visible growth. 
Molecular dynamics (MD) simulations.  MD simulations were performed using 
GROMACS 4.6.5 software and the AMBER03 protein and nucleic AMBER94 force-fields.  
Structures were boxed and solvated using the GROMACS modules ‘gmx editconf’ and ‘gmx 
solvate’.  The two DNA helical strands were placed centrally in a box and solvated using TIP3P 
(transferable intermolecular potential with 3 points).  The box was approximately 236.28 nm3
in size and filled with ~7,373 water molecules.  The system was then neutralised via the 
addition of an appropriate concentration of calcium ions into the box.   The Particle mesh Ewald 
method was used to analyse long-range electrostatic interactions and a 1.4 nm cut-off was 
applied to Lennard-Jones interactions.  Initial MD simulations were performed in a two-step 
process.  Following an energy minimization stage (EM), this was followed by MD simulation 
at 300 K for 100 ns allowing Ca2+ bridges to form between the DNA molecules.  The final 
positions of the DNA molecules and Ca2+ ions were calculated and placed inside a 318.83nm3
“box” with OligoG and filled with ~10,010 water molecules.  A second round of MD 
simulations was performed and run over 50 ns.  In a final model, the resultant positions of DNA 
and calcium ions from the initial models were employed and un-bound calcium ions removed 
from the simulation.  OligoG was then added and the modelling repeated as described above. 
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